Analysts Set Expectations for Zoetis' Q1 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS - Free Report) - Equities researchers at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Zoetis in a research report issued on Monday, April 21st. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $1.42 per share for the quarter, down from their previous estimate of $1.43. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis' Q2 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $6.06 EPS, FY2026 earnings at $6.78 EPS, FY2027 earnings at $7.42 EPS and FY2028 earnings at $8.05 EPS.

Other research analysts have also issued reports about the company. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus decreased their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $214.40.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $150.17 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a 50 day moving average price of $159.19 and a 200 day moving average price of $169.22. The company has a market cap of $67.00 billion, a price-to-earnings ratio of 27.45, a PEG ratio of 2.78 and a beta of 0.92. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently modified their holdings of ZTS. Callahan Advisors LLC lifted its stake in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after purchasing an additional 6,221 shares during the last quarter. CIBC Asset Management Inc grew its position in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after acquiring an additional 46,050 shares during the last quarter. Pensionfund Sabic increased its holdings in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock worth $1,825,000 after purchasing an additional 4,000 shares in the last quarter. Schroder Investment Management Group raised its position in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Finally, PFW Advisors LLC bought a new stake in shares of Zoetis during the fourth quarter worth about $1,764,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. Insiders own 0.16% of the company's stock.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.